- Home
- IMRN vs SYBX Comparison
IMRN vs SYBX Comparison
Compare IMRN & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- SYBX
- Stock Information
- Founded
- IMRN 1994
- SYBX N/A
- Country
- IMRN Australia
- SYBX United States
- Employees
- IMRN N/A
- SYBX 6
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- SYBX Health Care
- Exchange
- IMRN Nasdaq
- SYBX Nasdaq
- Market Cap
- IMRN 15.0M
- SYBX 15.9M
- IPO Year
- IMRN N/A
- SYBX N/A
- Fundamental
- Price
- IMRN $1.81
- SYBX $1.36
- Analyst Decision
- IMRN Strong Buy
- SYBX Buy
- Analyst Count
- IMRN 1
- SYBX 4
- Target Price
- IMRN $5.00
- SYBX $15.50
- AVG Volume (30 Days)
- IMRN 6.2K
- SYBX 11.7K
- Earning Date
- IMRN 11-26-2024
- SYBX 11-12-2024
- Dividend Yield
- IMRN N/A
- SYBX N/A
- EPS Growth
- IMRN N/A
- SYBX N/A
- EPS
- IMRN N/A
- SYBX N/A
- Revenue
- IMRN $3,271,194.00
- SYBX $2,777,000.00
- Revenue This Year
- IMRN N/A
- SYBX N/A
- Revenue Next Year
- IMRN N/A
- SYBX N/A
- P/E Ratio
- IMRN N/A
- SYBX N/A
- Revenue Growth
- IMRN 171.67
- SYBX 292.23
- 52 Week Low
- IMRN $1.59
- SYBX $1.22
- 52 Week High
- IMRN $5.96
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- IMRN 35.96
- SYBX 40.49
- Support Level
- IMRN $1.73
- SYBX $1.37
- Resistance Level
- IMRN $1.99
- SYBX $1.58
- Average True Range (ATR)
- IMRN 0.12
- SYBX 0.09
- MACD
- IMRN 0.02
- SYBX -0.00
- Stochastic Oscillator
- IMRN 20.42
- SYBX 0.00
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.